GLPwatch

Direct Effect of the Synthetic Analogue of Glucagon-Like Peptide Type 1, Liraglutide, on Mature Adipocytes Is Realized through Adenylate-Cyclase-Dependent Enhancing of Insulin Sensitivity.

Biochemistry (Mosc) · 2021

Last updated 2026-05-28

In a lab study, researchers found that liraglutide, a GLP-1 drug, directly improved insulin sensitivity in mature fat cells by activating an enzyme called adenylate cyclase. The study used a specific type of mouse fat cell (3T3-L1) and showed that liraglutide had a positive effect on how these cells responded to insulin.

AI summary of the abstract below.

JournalBiochemistry (Mosc), 2021
Citations4
Relative citation ratio0.23
NIH percentile15
Molecules liraglutide
Conditions studied Type 2 Diabetes, Obesity

Abstract

Incretin hormones analogues, including glucagon-like peptide type 1 (GLP-1), exhibit complex glucose-lowering, anorexigenic, and cardioprotective properties. Mechanisms of action of GLP-1 and its analogues are well known for pancreatic β-cells, hepatocytes, and other tissues. Nevertheless, local effects of GLP-1 and its analogues in adipose tissue remain unclear. In the present work effects of the GLP-1 synthetic analogue, liraglutide, on adipogenesis and insulin sensitivity of the 3T3-L1 adipocytes were examined. Enhancement of insulin sensitivity of mature adipocytes by the GLP-1 synthetic analogue liraglutide mediated by adenylate cyclase was demonstrated. The obtained results imply existence of the positive direct insulin-sensitizing effect of liraglutide on mature adipocytes.

Verbatim abstract via PubMed 33838634 ↗

Related research